G-CSF therapy for unexplained recurrent miscarriage

G-CSF therapy for unexplained recurrent miscarriage - G-CSF therapy for unexplained recurrent miscarriage

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005830

Enrollment

Registered

2011-06-22

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unexplained recurrent miscarriage

Interventions

Lenograstim, genetical recombination, granulocyte colony stimulating factor placebo (saline)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) no medical complication 2) no previous child-birth 3) experienced four or more consecutive spontaneous early miscarriages except chemical abortion 4) unexplained reason with detail examination of recurrent pregnancy loss

Exclusion criteria

Exclusion criteria: history of allergy to G-CSF

Design outcomes

Primary

Measure	Time frame
To compare the obstetrical outcome; the rate of live birth and spontaneous abortion, between G-CSF and placebo group in the intrauterine pregnancy	—

Secondary

Measure	Time frame
To evaluate the maternal side effects and the long term safety of children till six years	—

Countries

Japan

Contacts

Public ContactKinue Katano

Nagoya City University Graduate School of Medical Sciences Department of Obstetrics and Gynecology

og.kktn@med.nagoya-cu.ac.jp052-853-8241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026